Pernix Therapeutics (PTX) Misses Q3 EPS by 19c

Pernix Therapeutics (NASDAQ: PTX) reported Q3 EPS of ($0.18), $0.19 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $48.6 million versus the consensus estimate of $46.83 million.

For earnings history and earnings-related data on Pernix Therapeutics (PTX) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Gemini Space Station, Inc. (GEMI) Misses Q2 EPS by 32c
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance